Taken together, combined inhibition of PI3Kβ and MLK3 may be a promising therapeutic approach for GBM treatment, but an effective and BBB-penetrating drug delivery system is required prior to the clinical application. The gene discussed is MAP3K11; the disease is glioblastoma.